Cannabinoid receptors have been shown to interact with other receptors, including tumor necrosis factor receptor superfamily (TNFRS) members, to induce cancer cell death. When cannabinoids and death-inducing ligands (including TNF-related apoptosis-inducing ligand) are administered together, they have been shown to synergize and demonstrate enhanced antitumor activity in vitro. Certain cannabinoid ligands have been shown to sensitize cancer cells and synergistically interact with members of the TNFRS, thus suggesting that the combination of cannabinoids with death receptor (DR) ligands induces additive or synergistic tumor cell death. This review summarizes recent findings on the interaction of the cannabinoid and DR systems and suggests possible clinical co-application of cannabinoids and DR ligands in the treatment of various malignancies.
The cannabinoid system
The endocannabinoid system includes endogenous ligands (endocannabinoids), receptors, and regulatory proteins responsible for the synthesis, transport, signaling, and degradation of these molecules. The endocannabinoid system plays a crucial role in the regulation of many neurophysiological, cardiovascular, immunity, and energy homeostasis-related functions [1] [2] [3] [4] . At least two types of cannabinoid receptors, the cannabinoid type-1 (CB1) and cannabinoid type-2 (CB2), have been cloned and extensively characterized together with their endogenous and synthetic ligands both in vitro and in vivo [5] [6] [7] [8] [9] [10] . Most of the observed pharmacological effects of cannabinoids are due to the activation of the inhibitory G-protein coupled CB1 receptor, however, the likewise inhibitory G-protein coupled CB2 receptor also appears to play an important role in immune cell modulation, among other functions [11, 12] . Though also present in the periphery, CB1 receptors are predominantly localized at nerve terminals in the central nervous system (CNS), and their functional activation by cannabinoid ligands generally reduces neurotransmitter release, including GABA, dopamine, and others [13, 14] . The CB2 receptors are mainly restricted to the periphery, primarily on immune cells, and their activation leads to periodic cytokine release upon neuro-inflammation, infection, Abbreviations 2-AG, 2-arachidonyl-glycerol; AEA, anandamide; ALK, anaplastic lymphoma kinase; AREG, amphiregulin; Arvanil, N-arachidonoylvanillamine; CB1, cannabinoid type-1 receptor; CB2, cannabinoid type-2 receptor; CBD, cannabidiol; CNS, central nervous system; DD, death domain; DISC, death-initiating signaling complex; DL, death ligand; DR, death receptor; EGFR, epidermal growth factor receptor; ER, endoplasmatic reticulum; ERK, extracellular signal-regulated kinase; FADD, Fas-associated protein with death domain; FAN, factor associated with neutral sphingomyelinase activation; FasL, Fas ligand; MDK, midkine kinase; NADA, N-arachidonoyl dopamine; ROS, reactive oxygen species; SMases, sphingomyelinases; THC, tetrahydrocannabinol; TNFR, tumor necrosis factor receptor; TNFRS, tumor necrosis factor receptor superfamily; TRAIL, TNF-related apoptosis-inducing ligand.
or other stimuli [15] . However, recent studies have shown that the CB2 receptors might be present in certain subregions of the CNS, although their function in these regions has remained controversial and elusive [16] . As a result of their widespread distribution and pharmacological and physiological features, the endocannabinoid system is an appealing target for drug discovery and development, including for the treatment of cancer.
The cannabinoid system as a target in cancer
Cannabinoids such as D9-tetrahydrocannabinol (THC) (Marinol, marijuana) and its synthetic analog Nabilone (Cesamet) are primarily known for their usefulness in palliative therapy in cancer patients [17, 18] . These drugs can increase appetite, reduce pain, and reduce chemotherapy-associated nausea and vomiting. Many in vitro and in vivo studies also indicate that cannabinoid drugs can reduce tumor volume and induce cancer cell death [19] [20] [21] [22] . Both the CB1 and CB2 receptors, their endogenous ligands, and regulatory proteins are expressed, functionally active, and generally up-regulated in most tumor cell lines [2, 18, [23] [24] [25] . Interestingly, tumor cell viability and metastatic aggressiveness often correlate with overactivation of the endogenous cannabinoid system, and cell survival and cell death appear to be regulated at multiple levels [26] [27] [28] . Healthy, noncancerous cells usually have lower susceptibility to cannabinoid-induced cell death, and are less likely to undergo apoptosis upon cannabinoid stimulus. The most important tumor-suppressive regulatory effects of cannabinoid ligands on cancer cells are the dose-dependent inhibition of cell proliferation and initiation of cancer cell death by the activation of the extrinsic or intrinsic apoptotic pathways [29] . In some studies, cannabinoid administration has been shown to impair angiogenesis, metastasis, and tumor cell invasion, which might also suggest a potential application of cannabinoid drugs as lead compounds for the development of antiangiogenic or antimetastatic drugs [30, 31] . One limitation of the field however is that most of the mechanistic studies on cannabinoid-induced cancer cell death have been performed in glioblastoma cell lines [32] [33] [34] .
The nature of the downstream signaling events induced by cannabinoids can vary from drug to drug, and the observed effects may depend on the cellular model used. Despite these differences however, many studies have pointed to the common role of the universal proapoptotic sphingolipid molecule ceramide, and the importance of lipid rafts in the initiation and regulation of cannabinoid-induced cancer cell death [35] [36] [37] [38] [39] . Cannabinoid-induced death signaling can also target intracellular organelles such as mitochondria or endoplasmatic reticulum (ER), as well as essential, substantially protective cellular functions such as autophagy. These in turn can become overactivated, resulting in cell death in various types of cancer cells in culture [40] [41] [42] [43] . Changes in the expression pattern of stress-regulated transcriptional regulators that are involved in tumorigenesis as well as tumor progression might also be contributors to cannabinoid-mediated cell death [44] [45] [46] . All these findings together suggest that cannabinoid-mediated cancer cell death is a highly complex and finely tuned molecular event. A better understanding of the underlying molecular mechanisms will be necessary to be able to design better cannabinoid-based drugs for the treatment of various cancers.
The death receptor system
Apoptosis is a tightly controlled, genetically encoded cellular process, which is essential for embryonic development as well as normal tissue homeostasis [47] . Apoptosis is regulated by various molecules such as growth factors, cytokines, intracellular proteins, and cell damage markers [48, 49] . Specific cytokines, sometimes called death ligands (DL), such as tumor necrosis factor-alpha (TNFa), CD95L (Fas), tumor necrosis factor related apoptosis-inducing ligand (TRAIL), and the TNF-like protein 1A (TL1A) and their respective receptors belong to the tumor necrosis factor receptor superfamily (TNFRS) and are able to trigger apoptosis in every cell type [50] . There are at least six different death receptors (DRs) that are all capable of inducing extrinsic apoptotic cell death via activation by endogenous or exogenous ligands [51] . DL binding triggers receptor homotrimerization and recruitment of the death-initiating signaling complex (DISC) to their death domain (DD). A typical DISC is composed of a variety of different adaptor and regulatory proteins such as Fas-associated protein with death domain (FADD), cellular FLICE-like inhibitory protein, initiator caspase-8 and 10 and other death effector domaincontaining proteins. The activation of these molecules downstream leads to the disruption of the mitochondrial membrane, activation of executive caspases, and formation of the apoptosome [50] . This mechanism of apoptotic cell death induced by the activation of DRs is typical but not necessarily true for all DRs or cancer cells. For example, the primary role of the TNFa receptor-ligand system is the activation of NFkB, JNKs and MAPKs during the inflammatory response, while TNFa activation initiates apoptosis only under certain conditions [50, 52] . On the other hand, there is evidence to suggest that many cancer cells lack expression of or have a mutated version of the aforementioned DRs, which can make them resistant to death receptor-mediated cell death [53] [54] [55] [56] .
The dual role of autophagy in cell survival and cell death Autophagy is a tightly regulated, destructive, but not necessarily fatal mechanism by which cells disassemble, remove or recycle unnecessary or toxic cell components. Autophagy not only removes and neutralizes toxic or useless proteins and organelles within the cells, but also, it appears to be responsible for the elimination of damaged or nonfunctional mitochondria, a process called mitophagy. Since mitochondrial integrity is usually compromised during the activation of the extrinsic or intrinsic apoptotic pathways, the contribution of autophagy and its regulation of cannabinoid or DL-induced cell death might be critical [57] . For example, THC treatment of glioma cells has been shown to induce an imbalance in the dihydroceramide/ ceramide composition of the ER, which directs ER into autophagosomes and autolysosomes, leading to autophagy-mediated cancer cell death [37] . Similarly, other authors found THC, cannabidiol (CBD) and other synthetic cannabinoid ligands to induce ER destabilization and subsequent activation of autophagy, predominantly via the regulation of tyrosine kinase receptors and the TRPV2 receptor or the generation of reactive oxygen specie (ROS) in different tumor models [58] [59] [60] .
Several chemicals and anticancer drugs sensitize or desensitize cancer cells to TRAIL-induced autophagy. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, has been shown to increase the cell surface expression of both the DR4 and DR5 death receptors and together with TRAIL ligand, synergistically induced autophagy and cell death via JNK, Akt and extracellular signal-regulated kinase (ERK)-mediated mechanisms in human colon cancer cells [61] . The proteasome inhibitor bortezomide decreases the viability and proliferation of chondrosarcoma cells by increasing the expression of DR4 and DR5 receptors in the cell surface, increasing the level of autophagy markers and inducing apoptosis via an intrinsic mitochondria-dependent manner [62] . While these results suggest a synergistic effect on autophagy, other studies have indicated opposite, cell protective effects. Interestingly, Lim et al. [63] found that autophagy might be partially responsible for the TRAIL resistance of the human hepatocellular carcinoma cell line HepG2 since inhibition of autophagy or knockdown of ATG5 (autophagy protein 5) partially restored the cytotoxicity of recombinant human TRAIL and induced cell death via the activation of the DR4 receptor and JNK pathway. In another study, epigallocatechin gallat prevented tumor cell death by dose-dependently antagonizing the binding of TRAIL to DR4 and DR5 receptors and activating autophagy flux [64] . Genetic or pharmacological inhibition of autophagy flux has restored the sensitivity of tumor cells to TRAIL and induced cell death in human HCT116 colorectal cancer cells. These examples clearly demonstrate the dual role of autophagy in the fate of cancer cells and its significance for future combined anticancer drug therapies.
The death receptor system as a target in cancer
The direct application of DR cytokines in cancer therapy is usually limited by their toxicity, lack of selectivity, and poor efficacy [65] [66] [67] [68] [69] [70] . Despite these limitations, they represent a promising class of anticancer and anti-inflammatory drugs because of their ability to kill certain types of cancer cells, and for their regulatory effects on the immune system. Most of these proteins and their recombinant analogs have some toxicity to normal cells; however, some of them are better tolerated (like TRAIL) and cause less sideeffects than the others [71] .
In the beginning, CD95 or Fas-analogs were not effective anticancer agents since they could cause severe hepatocellular or other systemic damage [72] , or potentiate cell proliferation of cancer cells [73] . However, this latter effect proved to be less significant than its antitumorigenic effects in many models, thus CD95L blockers entered clinical trials for glioblastoma patients [50, 73] . These limitations began to be overcome with the discovery of TRAIL, which opened a new chapter in the discovery and development of DR cytokines as anticancer agents [74] . TRAIL is better tolerated with less systemic toxicity, and greater selectivity toward cancer cells. TRAIL also induces apoptotic cell death in many different cancer models, even in vivo [75, 76] . There are at least five DRs that can bind TRAIL, but only two of them, namely the DR4 and DR5, are able to mediate TRAIL-induced apoptotic cell death [77, 78] . TRAIL binds to both receptors with similar affinity and triggers apoptosis via the same pathway as CD95. These early encouraging preclinical results with recombinant TRAIL prompted the development of more agonist antibodies and the creation of clinical studies for patients with cancer (NCT01327612, NCT01088347). Though TRAIL proved to be the best tolerated and least toxic in vivo, the clinical results were disappointing at some points. This was due to the lack of specific biomarkers enabling patient-tailored therapy, and TRAIL only weakly induced apoptosis (NCT01327612, NCT01088347). These results overall suggest that DR ligands like TRAIL could be effective, low toxicity anticancer agents, but require a means to improve its efficacy.
Synergistic interaction of the cannabinoid and death receptor systems
Cancer cells often develop defense mechanisms to protect themselves from DL-induced cell death [79] . This may be due to mutation or other cellular changes that make them less susceptible to apoptosis, including loss of cell surface receptors and mutation or down-regulation of downstream apoptosis executive regulators [80, 81] . In addition, some cancer cells display less initial sensitivity to death-inducing ligands, which limits the therapeutic application of recombinant DLs for treating these cancers [79] . One strategy to overcome these therapeutic difficulties is to sensitize cancer cells to DR stimuli by drugs that are usually not toxic to cancer cells, such as steroids, [82] or that can cause substantial cell death on their own, such as cannabinoids [32] . Co-application of these drugs, including cannabinoids [83] , with DR ligands could potentially sensitize cancer cells to apoptotic stimuli.
Cannabinoid drugs make up one of the most promising classes of these drugs. Many studies have already focused on the co-application of cannabinoids and other anticancer agents to sensitize a plethora of cancer cell lines in vitro [20, [84] [85] [86] . Some of these results are suggestive for CB and DR interaction; however, the data in some of these studies do not definitively demonstrate this connection, which remains a hypothesis [85] . Though these studies are encouraging, caution should be taken when these drugs are co-administered in vivo. It should be taken into consideration that some cannabinoid drugs can promote cancer cell survival under certain conditions [20, 25, 87, 88] . The reason why certain cannabinoids support cancer cell survival while others efficiently kill cancer cells both in vitro and in in vivo models remains unclear. Nonetheless, combined administration of cannabinoids such as THC, anandamide (AEA), HU-210, and phytocannabinoids with anticancer drugs such as temozolomide, gemcitabine, paclitaxel, and 5-fluorouracil resulted in synergistic activity in reducing tumor volume and cell viability of glioma, melanoma and pancreatic cancer cells [89] [90] [91] [92] [93] . Interestingly, certain cannabinoids such as CBD, besides being able to kill a wide variety of tumor cells, has also been shown to alleviate some of the undesired effects of therapeutic THC administration such as convulsion, discoordination, and psychoactive effects, thus improving the tolerability of cannabis-based medicines in combination with anticancer agents [18] . Though these studies above show that cannabinoids potentiate the efficacy of chemotherapeutic drugs, recent in vitro studies have suggested that certain cannabinoid ligands can sensitize tumor cells to DR ligands and due to a synergistic effect, can induce cell death more efficiently in hepatocarcinoma or osteosarcoma cells [83, 86] . Unfortunately, in spite of these promising results, we were unable to find ongoing or completed clinical trials for the co-application of cannabinoid drugs and recombinant TRAIL ligands for patients with cancer.
Discussion
Mechanisms of action and interaction between the cannabinoid and death receptor systems
Ceramide as a first-line downstream regulator of cancer cell death
Initial studies have shown that cannabinoids induce apoptotic cell death of cancer cells through a CB1-or CB2-dependent stimulation of the de novo synthesis or release of the proapoptotic sphingolipid ceramide [39, 94, 95] . These data demonstrate that ceramide might play a critical role in cannabinoid-mediated cell death, though it is not completely clear how ceramide might facilitate cannabinoid-induced DR activation and subsequent cell death. It is widely accepted that sphingomyelinases (SMases) become activated by cannabinoid receptors and stress stimuli [96, 97] . In addition to extracellular stimuli, caspases have also been shown to be involved in the activation and translocation of SMases [98] [99] [100] . Mechanistically, there are several theories to delineate the mechanism of action of ceramide-induced cell death. Figure 1 summarizes the major pathways and possible interactions that have been known to be activated/regulated upon cannabinoid or TRAIL ligand challenge. It is believed that cannabinoid ligand binding to either the CB1 or CB2 receptor might trigger downstream signaling event(s) that activate intracellular activators of SMases, which in turn, produce ceramide. The induced ceramide might translocate into and reorganize the sphingolipid-and cholesterol-enriched membrane lipid raft, and create a platform for the interaction of multiple receptor molecules or adaptor proteins [101] [102] [103] . This clustering process might enable the transactivation or oligomerization of other receptors, for example DRs, that can also be activated to synergistically increase ceramide levels, amplifying ceramidedirected death signals [104] . Indeed, the activation of SMases and the release of ceramide have been shown to be important for the initiation of apoptosis by CD95 (Fas) and TNF ligands [98] . AEA transduced its inhibitory effects on human cholangiocarcinoma cell lines by stimulating the accumulation of ceramide, stabilization of lipid rafts, and the recruitment of Fas and Fas ligand (FasL) to the lipid rafts, while another endocannabinoid, 2-arachidonyl-glycerol (2-AG), was shown to increase cholangiocarcinoma cell growth and disrupt the lipid raft structure in the cell membrane [35] . In addition to creating a high receptor density ceramide-enriched platform for signal transduction, ceramide might also facilitate interactions between receptor and intracellular signaling molecules, which are constitutively and actively present in lipid rafts. These include small G-proteins and membrane-bound kinases [101, 102] . Ceramide can also be metabolized into secondary messengers in the lipid raft that can be translocated into the cytosol and alter the activity of enzymes or cell organelles involved in apoptotic signaling pathways [105, 106] .
Tumor necrosis factor-alpha is the most physiologically pleiotropic cytokine, and also an endogenous DR ligand, which is primarily responsible for the regulation of inflammatory responses. However, TNFa has also been shown to be a mediator of cannabinoidinduced ceramide-mediated colon cancer cell death [94] . Though the CB2 receptor expression level was higher in the cells, either CB1 or CB2 receptor activation induced apoptosis not through de novo ceramide synthesis but through a different mechanism of action. It was suggested that the functional coupling of CB1 receptors to sphingomyelinases might involve different adaptor proteins, one of which is the factor associated with neutral sphingomyelinase activation (FAN). It is also known that FAN binds to a cytoplasmic portion of the 55-kDa tumor necrosis factor receptor (TNFR), the so-called neutral sphingomyelinase-activating domain, thereby coupling the receptor to sphingomyelin breakdown [107] . Interestingly, sustained ceramide accumulation through enhanced de novo synthesis has been also shown to play a significant role Fig. 1 . General signal transduction mechanisms known so far to regulate cannabinoid-induced DR mediated cancer cell death. The most upstream key molecule that can orchestrate and initiate death signals appears to be ceramide, which can be increased either by cannabinoid (CB1 or CB2) or death receptor (DR4 or DR5) activation. Ceramide can act on many regulators and signaling molecules that can eventually cause mitochondrial or ER damage, ultimately leading to apoptotic cell death. Interestingly, either cannabinoid or DR activation can also be antiapoptotic via the activation of kinases and transcription factors that promote the activation of prosurvival pathways. It is not known, however, whether the cannabinoid and DRs are able to form heterodimers or can directly interact with each other, and then undergo endocytosis or other desensitization mechanisms. Translocation of proapoptotic molecules, cross-activation, and subsequent amplification of lethal signals may also be possible.
in CB2 receptor activation-induced apoptosis in tumor cells, including glioma [108] , leukemia [109] , and pancreatic cancer [44] cells. However, the precise molecular mechanisms involved in the CB2 receptor-mediated generation of ceramide are still unknown. In this study, the authors also showed that both CB1 and CB2 receptor activation stimulated ceramide synthesis in colon cancer cells, and its abrogation by the ceramide synthase inhibitor fumonisin B1 prevented the induction of apoptosis that occurred after the administration of different cannabinoids. Moreover, ceramide expression was significantly higher in tumor xenografts treated with cannabinoid than those treated with vehicle. Some of the downstream targets of ceramide involved in cannabinoid-induced apoptosis have also been recently identified. Carracedo et al. [45] have shown that cannabinoid-induced ceramide synthesis in glioma and pancreatic cancer cells led to cell apoptosis through the up-regulation of the stress-regulation protein p8 and the endoplasmic reticulum stress-related genes ATF-4 and TRB3. However, little is known about the signaling pathways underlying the promotion of ceramide synthesis through cannabinoid receptor activation.
These studies suggest that cannabinoid drugs differentially regulate DR activation and cell death, and that cannabinoid-mediated DR activation seems to strongly depend on ceramide release and the composition of lipid rafts. It is not clear, however, whether this is a unique cannabinoid-mediated regulatory mechanism for the Fas and TNF receptors or this is a universal phenomenon across the different types of DRs. It is not clear either whether cannabinoid receptors can functionally interact and internalize together with the DRs upon cannabinoid or DR ligand binding or if this feature is only typical for certain DRs such as for the CD95/Fas [110] .
Cannabinoids and death receptors regulate tumor cell death via different mechanisms
The most recent findings on cannabinoid-DR co-activation-induced cell death are summarized in Table 1 . An elegant in vivo study on cannabinoid-induced Fas receptor-mediated cell death found that differential activation of the cannabinoid receptors, along with down-or up-regulation of the FADD and its phosphorylation state, appears to be critical for a decision whether or not the neuronal cells undergo apoptotic cell death [111] . FADD is a multifunctional cytosolic adaptor protein, and recruitment of this protein upon Fas receptor activation activates the extrinsic apoptotic pathway. Based on these findings, the CB1 selective agonist WIN55212-2 seemed to regulate FADD phosphorylation and down-regulation. Also, cell survival depended on the treatment condition (acute or chronic) and a sophisticated balance between the activation of the pro-and antiapoptotic downstream signaling pathways. This apparently controversial finding can be explained if it is kept in mind that DR activation is not always proapoptotic for a cell, but can also be antiapoptotic, for example through the activation of prosurvival pathways [112, 113] .
Fas receptor activation and subsequent FADD recruitment were also observed for an atypical hybrid cannabinoid ligand, called N-arachidonoylvanillamine (Arvanil) [114] . This hybrid molecule shows a high structural homology to endovanilloid N-arachidonoyl dopamine (NADA), and was designed to simultaneously target both the TRPV1 and CB1 receptors. This ligand seems to mediate its apoptotic effects through the generation of ROS and the activation of the Fas receptor and various downstream caspases in lymphoid Jurkat T cells. The Arvanil-mediated apoptotic response was found to be significantly inhibited in a Jurkat-FADDDN cell line, which constitutively express a dominant negative form of the adapter molecule FADD, preventing apoptosis in response to Fas (CD95) stimulation. Additionally, Arvanil-induced apoptotic cell death appeared to be CB1 and TRPV1 receptor-independent, suggesting the involvement of a third party molecule such as ceramide in the regulation of Fas-dependent cell death. Indeed, increased ROS production has been shown to activate sphingomyelinases in the lipid rafts of the cell membrane, which in turn elevates the intracellular level of ceramide [115] . Ceramide release might favor DISC assembly and can activate the apoptotic signaling cascade. This hypothesis is in accordance with another report showing that Fas-resistant cell lines are also resistant to apoptosis induced by exogenous ceramide [116] . ROS generation can also cause mitochondrial membrane perturbations leading to mitochondrial pore opening, which leads to the release of cytochrome c and further activation of apoptosis [117] . Costa et al. have published that AEA induces apoptosis in primary human cytotrophoblasts and human trophoblast-like choriocarcinoma cell lines, primarily through the generation of ROS and reactive nitrogen species as well as caspase and NfjB pathway activation. Their findings suggest a crosstalk between the intrinsic and extrinsic apoptotic pathways and shed further light on the complexity of AEA-induced apoptotic cell death, which may involve cancerous and noncancerous cells [118] .
Other members of the DR family such as TRAIL receptors and TRAIL ligand can be activated or released by treatment with cannabinoid drugs.
WIN55212-2, a well-studied CB1 selective agonist, has been shown to be capable of sensitizing TRAIL-resistant HepG2, Hep3B, and SK-Hep1 hepatocellular cancer cells to TRAIL-induced apoptosis [86] . The reported data showed that combined treatment with low doses of WIN55212-2 and TRAIL dramatically increased apoptosis in these cancer cell lines. The apoptotic event appeared to be a consequence of at least two independent events. First, WIN55212-2 treatment up-regulated DR5 receptor expression, orchestrated by an early activation of the stress regulated nuclear protein-1/p8 and CHOP. Second, down-regulation of both phospho-Akt and prosurvival factors of the inhibitory IAP family were also found to be responsible for the observed additive apoptotic effects. In combination, these effects sensitized the cells to TRAIL-induced cell death. Interestingly, in another study, WIN55212-2 could induce apoptotic cell death in MG63 and Saos-2 human osteosarcoma cells only in the presence of TRAIL ligand, which is possibly mediated by the up-regulation of the tumor suppressor factor PAR-4 [83] . However, WIN55212-2/TRAIL cotreatment induced cell death was not restricted to apoptosis, since WIN55212-2 treatment alone could induce a plethora of cellular events that could sensitize cancer cells to other lethal extracellular stimuli. Accordingly, their results also showed that WIN55212-2 induced G2/M cell cycle arrest, which was thought to be associated with the production of ER stressrelated proteins such as GRP78, CHOP, and TRB3. In these treated osteosarcoma cells, the authors observed evidence for the formation of autophagosomes and autolysosomes. Additionally, WIN55212-2 induced morphological changes in MG63 cells such as an increase in cell size and an enhanced cytoplasmic vacuolization. The sensitizing effect of WIN55212-2 to TRAIL-induced apoptosis does not seem to be depleted by the aforementioned mechanisms. The same authors have recently published novel findings on how WIN55212-2 can regulate the function and expression of proteins such as the Secreted Protein Acidic and Rich in Cystein (SPARC, also called osteonectin). SPARC is an acidic extracellular matrix protein that modulates cell-cell and cell-matrix interaction, thus playing a crucial role in metastasis and angiogenesis [84] . This protein is often overexpressed in neoplastic cells, and is thought to be antitumorigenic in certain cancer cells. WIN55212-2 was shown to increase the level of both SPARC protein and mRNA in a time-dependent manner, making the cells susceptible to WIN55212-2/TRAIL-induced cell death. In addition, SPARC activated and translocated caspase-8 to the plasma membrane, and initiated the extrinsic apoptotic pathway. In spite of the limited data available, these results show that cannabinoid ligands can regulate cancer cell death through multiple pathways and mechanisms, and seem to be potent sensitizing agents to DR ligand (TRAIL)-induced cell death, even in TRAIL-resistant cells.
TRAIL-and cannabinoid-related mechanisms of resistance in cancer cells
It is well-known that tumors usually consist of heterogeneous cell populations, which exhibit particular molecular characteristics that determine their responsiveness to various anticancer drugs. Figure 2 summarizes the most common pathways responsible for the development of resistance to cannabinoid drugs or DR ligands. One of these characteristics appears to be CB receptor expression and function. Cannabinoid receptors are prototypical Class B GPCRs, similar to the badrenergic or opioid receptors [119, 120] , and thus are prone to desensitization and internalization upon longterm exposure to certain cannabinoid drugs [121] . Consequently, cannabinoid receptor trafficking and turnover can be a first-line reason for the loss of sensitivity to cannabinoid-induced cancer cell death.
Sensitivity of tumor cells to cannabinoids is often correlated with the expression of particular sets of genes, which might be independent of cannabinoid signaling and do not necessarily result in changes in the expression level of cannabinoid receptors. However, up-regulation of such genes and their protein products might have an impact on other factors and on the overall resistance of cancer cells to cannabinoid-based anticancer therapies. For example, up-regulation of midkine kinase (MDK), also called neurite growthpromoting factor 2 (NEGF-2), is associated with poor survival rate and less responsiveness to THC treatment in patients with glioblastoma tumors [122] [123] [124] . Mechanistically, MDK seems to bind and stimulate the activity of another pro-oncogenic protein, the anaplastic lymphoma kinase (ALK), which inhibits THCevoked autophagy-mediated cell death in vitro [124, 125] . Similarly, enhanced expression of the heparin-bound EGFR ligand amphiregulin (AREG) has been shown to confer resistance to THC-sensitive tumors by stimulating the activity of the ERK [126] .
The importance of cellular localization of TRAIL/ DRs in terms of resistance mechanisms has been reviewed recently [127] . TRAIL-induced apoptosis is regulated at the transcriptional and protein levels and the localization pattern of TRAIL/DRs appears to be significant for TRAIL-induced apoptosis [127] [128] [129] . At the cell surface, TRAIL-induced cell death can be inhibited by binding of TRAIL to the death-domain lacking decoy receptors DcR1 and DcR2 [130] . At the subcellular level, TRAIL-induced apoptosis can be inhibited by overexpression of c-FLIP, preventing DISC formation [131] . It is also known that defects in death-receptor membrane transport are usually sufficient to confer resistance to apoptosis though spatial cytoplasmic and nuclear translocations of both deathinducing TRAIL receptors, which are possible mechanisms to explain resistance to TRAIL-induced cancer cell death [132] . Nuclear translocation of DR5 receptor can confer resistance to human tumor cells, primarily through an importin-b1-dependent mechanism [133] . Co-immunoprecipitation experiments also showed that both DR4 and DR5 can form a secondary signaling complex, which contains receptor-interacting protein 1, FADD, caspase-8, NEMO, and TNF receptor-associated factor 2 [134] . This protein complex appeared to be important for the activation of various molecules such as NFjB and MAP kinases.
Death receptor expression can also be up-regulated or repressed, which can contribute to TRAIL resistance in cancer cells. Two first-line regulators are p53 and CHOP, and the latter has an important role in ER stress response and has a binding site on the TNFRSF10B promoter that regulates DR5 receptor transcription [135, 136] . Sequestration of DR4 and DR5 receptors into autophagosomes results in their down-regulation, thus inhibition of autophagy leads to increased TRAIL responsiveness [137] . Studies in breast cancer cell lines revealed that constitutive endocytosis of DR4 and DR5 causes deficient cell surface expression regardless of mRNA and total protein level [137, 138] . It was also shown that reduction in cell surface expression of TRAIL DRs is followed by a rapid internalization of TRAIL with DR4 and DR5 receptors in MDA-MB-231 cells [139] . Similar mechanisms have been reported for clathrin-mediated DR5 endocytosis upon TRAIL binding in several different cell lines [140] .
Although sequestration of DRs might be a reversible dynamic process, once internalized, DRs can undergo ubiquitin-mediated degradation. The use of various proteasome inhibitors was shown to affect TRAIL sensitivity in different cell types. Bortezomib, for example, was shown to increase both total and surface expressions of DR4 and DR5 in NSCLC cell lines [141] . Interestingly, not only receptor trafficking but post-translational modification and maturation of DRs can alter the sensitivity of tumor cells. O-glycosylation has been shown to control TRAIL sensitivity in various human cancer cell lines [142] . For example, O-glycosylation of DR5, which possesses multiple O-glycosylation sites, promotes receptor clustering and increases TRAIL responsiveness. siRNA knockdown of syndecan-1, which is an integral membrane protein responsible for cell proliferation and migration, increased TRAIL-induced apoptosis through elevated expression of TRAIL receptor Oglycosylation enzymes [143] .
Similar to cannabinoid receptors, clustering of DRs in lipid rafts is another important factor for determining TRAIL sensitivity and for the recruitment of the necessary death signaling components to initiate DISC formation and subsequent apoptotic cell death [103, 144] . For example, Quercetin, an anticancer flavonoid, was shown to increase TRAIL sensitivity of colon cancer cells by redistributing DR4 and DR5 receptors into lipid rafts at the plasma membrane without affecting mRNA or protein levels [145] . Bufalin also enhanced TRAIL-induced apoptosis in breast cancer cells via a similar mechanism of DR redistribution [146] . Long-term exposure to cannabinoid agonists can lead to cannabinoid receptor desensitization and/or internalization. Both the cannabinoid and DRs are capable of internalization and subsequent ubiquitin-mediated degradation or recycling. It is not clear, however, whether these internalized cannabinoid and DR complexes are able to initiate signals from the endosomes. DRs can also form secondary signaling complexes and can activate NFkB or MAPKs or translocate to the nucleus where they regulate the transcription of multiple genes. However, the expression of DRs is also under the control of CHOP and p53 proteins. Resistance to cannabinoid drugs can also develop due to up-regulation of kinases (MDK or ALK) or other molecules (AREG) that can lead to less responsiveness to the cannabinoid treatment.
As summarized above, many factors can influence TRAIL and cannabinoid drug resistance. Factors determining cancer cell sensitivity and resistance to cannabinoids and TRAIL ligand are summarized in Fig. 2 . Taking into account that these two receptor systems might be able to interact in lipid rafts, the number of possible signaling and other regulatory pathways affecting receptor transcription, maturation and trafficking is considerable. Currently, it is not clear how cannabinoid drugs influence the transcription, maturation or trafficking of DR4 and DR5 death receptors and whether cannabinoid drugs are able to restore the function of DRs and their trafficking as part of the sensitization process.
Clinical significance of the cannabinoid and death receptor systems in the treatment of cancer
The clinical application of cannabinoids is currently restricted to palliative uses in cancer. However, with the increasing number of promising pilot studies and preclinical data, the antitumor effects of cannabinoids are beginning to be more widely clinically evaluated. Current clinical studies mostly focus on patients with different types of glioblastoma, which are the most common and debilitating tumors of the CNS [147] . These clinical results indicate that patients at least partially respond to cannabinoid treatments, and cellular and molecular examination of tissue samples indicates that the main reasons for the shrinkage of tumors appear to be the induction of autophagy and apoptosis and the decrease in vascularization of the tumor tissue [20, 148] . Though these studies are encouraging and further strengthen the potential use of cannabinoids in cancer therapy, further studies should be aimed at optimizing the use of cannabinoids in terms of patient selection based on genotyping or biomarker screening, or in combination with other anticancer agents such as recombinant DR ligands. Currently, three types of death-receptor ligand products, namely TNF blockers (NCT02778789, NCT02353780) CD95L inhibitors (NCT02269878, NCT00437736), and TRAIL agonists (NCT03083743, NCT00508625, NCT00094848) (https://clinicaltrials.gov) are under clinical recruitment, assessment or already in clinical practice. However, further in-depth research will be required to find predictive markers for tumor/DR ligand sensitivity and to determine the precise molecular crosstalk between cannabinoids and DR ligands. This will be necessary in order to be able to optimize the pharmacodynamic and pharmacokinetic features of clinical cannabinoid-based combination therapies.
Conclusion and future perspectives
Most of the in vivo animal and clinical studies show that cannabinoids, regardless of their origin and structural background, are capable of effectively suppressing tumor cell growth and invasion. Though the number of clinical studies evaluating cannabinoid efficacy in human subjects is very limited, these studies usually indicate that cannabinoids could be a safe and effective choice for anticancer drug therapies. Both the cannabinoid and DR systems are often up-regulated or overactivated in cancer cells, meaning their ligands can selectively induce cancer cell death alone or in combination, with low toxicity in normal tissue. Thus, these receptors and their ligands may provide effective and selective targets and tools for cancer therapy. Recent findings have shown that cannabinoid drugs are able to selectively sensitize cancer cells that can subsequently undergo DR-mediated cell death. Though the underlying molecular mechanisms are still not well understood, the continuously growing body of in vitro and in vivo evidence and preclinical 'proofof-concept' studies strongly suggest that combined targeting of the cannabinoid and DR systems could improve clinical efficacy over single drug therapy. Since cannabinoid and DR-targeting drugs have been shown to have an acceptable safety profile, compared to other clinically relevant anticancer agents, such therapies also promise to elicit fewer toxic side-effects. However, further clinical trials would be necessary to validate the efficacy and side-effect profile of combination therapies. In the long term, the development of multifunctional single molecule therapies that could simultaneously target the cannabinoid and DRs may further simplify treatment, improve therapeutic efficacy, and reduce off-target side-effects. Such therapies also have potential promise in the treatment of particularly difficult cancer types, such as glioblastoma multiform, and all with the promise of greatly reduced side-effects compared with current and traditional chemotherapeutic approaches. 
